Osseon launches Osseoflex BT Steerable Bone Tamp for physicians

Osseon® Therapeutics announced today at the Society of Interventional Radiology's (SIR) Annual Meeting the launch of the Osseoflex BT Steerable Bone Tamp.  The steerable bone tamp is designed to allow percutaneous access to sclerotic bone.  The Osseoflex BT features the same proprietary technology found in the Osseoflex® Steerable Needle and Osseoflex® DR Steerable Drill.  The Osseoflex BT articulates up to 60 degrees( and, when used in conjunction with the Osseoflex Needle, the Bone Tamp allows unipedicular access to vertebral compression fractures previously considered inaccessible due to dense, sclerotic bone or malignant tissue.  The Bone Tamp also provides clinicians with a percutaneous access option to cancellous bone in other areas of the body.

"The Osseoflex BT is the newest addition to the Osseon suite of steerable, minimally invasive devices," said John Stalcup, Ph.D., Osseon's CEO. "In the coming months, we will continue to develop and introduce complementary innovative products to address physician and patient needs."

Osseon Therapeutics currently markets the Osseoflex Steerable Needle, Osseoperm® Bone Cement, Osseoflex DR Steerable Drill, and Osseoflex Access Kit.  Together, the Osseoplasty Suite represents unparalleled products for physicians involved in the treatment vertebral compression fractures associated with osteoporosis, myelomas, and acute trauma.

Source:

Osseon Therapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds bone density loss associated with levothyroxine